Search results for "Narcotic"

showing 10 items of 106 documents

Sudden severe abdominal pain after a single low dose of paracetamol/codein in a cholecystectomized patient: learning from a case report.

2009

We report the case of an elderly patient with diastolic heart failure and renal insufficiency admitted to hospital as he complained of having a history of hypogastric pain and dysuria without fever due to renal lithiasis and urinary infection. Because the pain was persistence, and considering the presence of renal dysfunction, it was administered a single low dose of paracetamol/codein (500/30 mg). After about 1 hour of the administration, he suddenly complained of the onset of a lancinating epigastric pain radiating to the whole abdomen and retrosternum accompanied by nausea. The electrocardiogram (EKG) was negative for myocardial infarction and computed tomography excluded aortic dissecti…

MaleSpasmmedicine.medical_specialtyAbdominal painmedicine.medical_treatmentabdominal pain paracetamolSeverity of Illness IndexEpigastric painSphincter of OddimedicineHumansDysuriaCholecystectomyPharmacology (medical)Sphincter of OddiContraindicationAcetaminophenAgedPharmacologyCodeinebusiness.industryGeneral MedicineAnalgesics Non-Narcoticmedicine.diseaseAbdominal PainSurgeryAnalgesics OpioidDrug CombinationsAcute abdomenAnesthesiaAcute pancreatitisCholecystectomymedicine.symptombusiness
researchProduct

Role of central oxytocin in the inhibition by endotoxin of distension-stimulated gastric acid secretion

2000

The gastric acid hyposecretory state associated with endotoxemia is mediated by a nervous reflex involving the central nervous system. The aim of the present study was to analyse the central effects of different peptides on distension-stimulated gastric acid secretion and the endogenous role of such peptides on the hyposecretory effects of endotoxin. The effect of an intracisternal (i.c.) administration of oxytocin, vasopressin, corticotropin releasing factor (CRF), bombesin, somatostatin and the opioid receptor agonist BW443C or an intravenous (i.v.) injection of a small dose of endotoxin on distension-stimulated gastric acid secretion was studied in the continuously perfused stomach of an…

MaleVasopressinendotoxinCorticotropin-Releasing HormonevasopressinNarcotic AntagonistsGastric DilatationOxytocinchemistry.chemical_compoundVasoconstrictor AgentsReceptorChemistryStomachBombesincorticotropin-releasing factorGeneral MedicineSomatostatinmedicine.anatomical_structurebombesinReceptors Oxytocingastric acid secretionBombesinFemaleSomatostatingastric distensionOligopeptidesAntidiuretic Hormone Receptor Antagonistshormones hormone substitutes and hormone antagonistsmedicine.drugmedicine.medical_specialtyVasopressinsReceptors Corticotropin-Releasing HormoneGastric AcidAdrenergic AgentsInternal medicineoxytocinmedicineAnimalsRats WistarInjections IntraventricularPharmacologyDose-Response Relationship Drugcentral nervous systemOxytocin receptorEndotoxemiaHormonesRatsEndotoxinsReceptors BombesinEndocrinologyOxytocinGastric MucosaGastric acid
researchProduct

Gene Transcription Alterations Associated with Decrease of Ethanol Intake Induced by Naltrexone in the Brain of Wistar Rats

2006

Preclinical and clinical studies suggest that the administration of the opioid antagonist naltrexone decreases the intake of ethanol. However, the neuroplastic adaptations in the brain associated to reduction of ethanol consumption remains to be elucidated. The aim of the study was to identify gene transcription alterations underlying the attenuation of voluntary ethanol intake by administration of naltrexone in rats. Increasing doses of naltrexone (0.7 mg/kg, 4 days and 1.4 mg/kg/day, 4 days) to rats with acquired high preferring ethanol consumption (>3.5 g of ethanol/kg/day) decreased voluntary ethanol intake (50%). Voluntary ethanol consumption altered mu-opioid receptor function in the …

Malemedicine.medical_specialtyAlcohol DrinkingTranscription Geneticmedicine.drug_classNarcotic AntagonistsNucleus accumbensPharmacologyNaltrexoneInternal medicineImage Processing Computer-AssistedmedicineAnimalsRats WistarOpioid peptideIn Situ HybridizationBrain ChemistryPharmacologyEthanolTyrosine hydroxylaseChemistryOlfactory tubercleCentral Nervous System DepressantsEnkephalin Ala(2)-MePhe(4)-Gly(5)-NaltrexoneRatsAnalgesics OpioidVentral tegmental areaPsychiatry and Mental healthmedicine.anatomical_structureEndocrinologynervous systemGuanosine 5'-O-(3-Thiotriphosphate)HypothalamusAutoradiographyOpioid antagonistmedicine.drugNeuropsychopharmacology
researchProduct

The Novel μ-Opioid Receptor Antagonist GSK1521498 Decreases Both Alcohol Seeking and Drinking: Evidence from a New Preclinical Model of Alcohol Seeki…

2015

Distinct environmental and conditioned stimuli influencing ethanol-associated appetitive and consummatory behaviors may jointly contribute to alcohol addiction. To develop an effective translational animal model that illuminates this interaction, daily seeking responses, maintained by alcohol-associated conditioned stimuli (CSs), need to be dissociated from alcohol drinking behavior. For this, we established a procedure whereby alcohol seeking maintained by alcohol-associated CSs is followed by a period during which rats have the opportunity to drink alcohol. This cue-controlled alcohol-seeking procedure was used to compare the effects of naltrexone and GSK1521498, a novel selective μ-opioi…

Malemedicine.medical_specialtyAlcohol Drinkingmedia_common.quotation_subjectNarcotic AntagonistsDrug-Seeking BehaviorDrug Evaluation PreclinicalReceptors Opioid muPoison controlAlcoholContext (language use)Choice BehaviorNaltrexonechemistry.chemical_compoundSpecies SpecificitymedicineAnimalsPsychiatrymedia_commonPharmacologyDose-Response Relationship DrugAddictionAbstinenceTriazolesNaltrexoneRatsPsychiatry and Mental healthDisease Models AnimalchemistryAlcohol DeterrentsAnesthesiaIndansCommentaryConditioning OperantBlood alcohol contentBlood Alcohol ContentCuesPsychologyAlcohol-Related DisordersReinforcement Psychologymedicine.drugAlcohol DeterrentsNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
researchProduct

Modulation by peripheral opioids of basal and distension-stimulated gastric acid secretion in the rat.

1992

1. The influence of opioids in modulating gastric acid secretory responses has been investigated in the continuously perfused stomach of the anaesthetized rat. 2. Intravenous administration of morphine (0.75-3 mg kg-1) or the peripherally acting enkephalin analogue, BW443C (0.75-3 mg kg-1), substantially augmented acid secretion in basal conditions. These effects were significantly inhibited by the opioid antagonists naloxone (1 mg kg-1) and the peripherally acting N-methylnalorphine (2 mg kg-1). When administered alone, neither opioid antagonist influenced basal acid output. 3. Acid secretory responses to different levels of gastric distension (5-20 cmH2O) were significantly and dose-depen…

Malemedicine.medical_specialtyNarcotic AntagonistsNalorphine(+)-NaloxoneDistensionDeoxyglucoseGastric AcidInternal medicineNalorphineGastrinsmedicineAnimalsInsulinGastrinPharmacologyMorphinebusiness.industryNaloxoneGastric distensionRats Inbred StrainsRatsPentagastrinEndocrinologyOpioidInjections IntravenousGastric acidFemalePentagastrinmedicine.symptombusinessOligopeptidesmedicine.drugResearch ArticleHistamine
researchProduct

Effects of endotoxin on neurally-mediated gastric acid secretion in the rat.

1998

Abstract The effects of a peripheral administration of E. coli endotoxin on neurally-mediated gastric acid secretion and the role of endogenous opioids or PAF receptors in endotoxin effects have been evaluated in the continuously perfused stomach of the anaesthetized rat. Gastric acid secretion stimulated by distension (20 cm H2O) was reduced dose-dependently by single intravenous bolus injection of endotoxin (0.1–10 μg kg−1). Doses of 5 μg kg−1 induced a peak reduction of distension-stimulated acid output and significantly reduced the secretory response induced by an intravenous bolus of 2-deoxy-d-glucose (150 mg kg−1). This dose of endotoxin did not significantly modify mean systemic arte…

Malemedicine.medical_specialtymedicine.drug_classNarcotic AntagonistsPharmaceutical ScienceBlood PressureReceptors Cell Surface(+)-NaloxonePlatelet Membrane GlycoproteinsDistensionDeoxyglucoseReceptors G-Protein-CoupledGastric AcidOpioid receptorInternal medicinemedicineEscherichia coliAnimalsRats WistarEndogenous opioidPharmacologyDose-Response Relationship Drugbusiness.industryNaloxoneGastric distensionStomachAntagonistAzepinesTriazolesReceptor antagonistRatsEndotoxinsEndocrinologyOpioid PeptidesReceptors OpioidGastric acidFemalemedicine.symptombusinessPlatelet Aggregation InhibitorsThe Journal of pharmacy and pharmacology
researchProduct

‘Not at all what I had expected’: Discontinuing treatment with extended-release naltrexone (XR-NTX): A qualitative study

2021

Background: Extended-release naltrexone (XR-NTX), an opioid antagonist, has demonstrated equal treatment outcomes, in terms of safety, opioid use, and retention, to the recommended OMT medication buprenorphine. However, premature discontinuation of XR-NTX treatment is still common and poorly understood. Research on patient experiences of XR-NTX treatment is limited. We sought to explore participants' experiences with discontinuation of treatment with XR-NTX, particularly motivation for XR-NTX, experiences of initiation and treatment, and rationale for leaving treatment. Methods: We conducted qualitative, semi-structured interviews with participants from a clinical trial of XR-NTX. The study…

Malemedicine.medical_specialtymedicine.drug_classNarcotic Antagonistsmedia_common.quotation_subjectMedicine (miscellaneous)Injections IntramuscularNaltrexonemedicineHumansVDP::Medisinske Fag: 700PsychiatryQualitative Researchmedia_commonbusiness.industryClinical Studies as TopicAbstinenceOpioid-Related DisordersNaltrexoneBuprenorphineDiscontinuationAnalgesics OpioidClinical trialPsychiatry and Mental healthClinical PsychologyVDP::Medisinske Fag: 700::Helsefag: 800Delayed-Action PreparationsFemalePshychiatric Mental HealthThematic analysisbusinesshuman activitiesOpioid antagonistQualitative researchmedicine.drugBuprenorphine
researchProduct

High dose naloxone does not improve cerebral or myocardial blood flow during cardiopulmonary resuscitation in pigs

1997

In a prospective, randomized, placebo-controlled, double-blind trial we tested the hypothesis that naloxone given during cardiopulmonary resuscitation (CPR) enhances cerebral and myocardial blood flow. Twenty-one anesthetized, normoventilated pigs were instrumented for measurements of right atrial and aortic pressures, and regional organ blood flow (radiolabeled microspheres). After 5 min of untreated fibrillatory arrest, CPR was commenced using a pneumatic chest compressor/ventilator. With onset of CPR, an i.v. bolus of 40 micrograms/kg b.w. of epinephrine was given, followed by an infusion of 0.4 micrograms/kg per min. After 5 min of CPR, either naloxone, 10 mg/kg b.w. (group N, n = 11) o…

Mean arterial pressureSwineNarcotic Antagonistsmedicine.medical_treatmentHemodynamicsEmergency NursingBolus (medicine)Coronary CirculationAnimalsMedicineCardiopulmonary resuscitationSalineAcid-Base EquilibriumDose-Response Relationship DrugNaloxonebusiness.industryHemodynamicsBlood flowCardiopulmonary ResuscitationCerebrovascular CirculationAnesthesiaEmergency MedicineArterial bloodCardiology and Cardiovascular MedicinebusinessPerfusionResuscitation
researchProduct

Possible involvement of nitric oxide in morphine-induced miosis and reduction of intraocular pressure in rabbits.

2006

The role of μ3 opioid receptors in morphine-induced intraocular pressure (IOP) lowering effect and miosis was evaluated in conscious, dark-adapted New Zealand white (NZW) rabbits using a masked-design study. IOP and pupil diameter (PD) measurements were taken at just before and 0.5, 1, 2, 4, 6 h after monolateral instillation of morphine (10, 50 and 100 μg/30 μl) as compared to vehicle administered in the contralateral eye. Morphine-induced ocular effects were challenged by a pre-treatment with the non-selective opioid receptor antagonist, naloxone (100 μg/30 μl), the nitric oxide synthase inhibitor, Nω-nitro-l-arginine methyl ester (l-NAME, 1%, 30 μl), or the non-selective μ3 opioid recept…

MiosisIntraocular pressureTime FactorsPupil diametergenetic structuresmedicine.drug_classNarcotic AntagonistsReceptors Opioid muRabbit(+)-NaloxonePharmacologyEyeNitric OxideNitric oxidechemistry.chemical_compoundOpioid receptormedicineEnzyme InhibitorAnimalsEnzyme InhibitorsIntraocular PressurePharmacologybiologyDose-Response Relationship DrugMorphineAnimalNaloxoneMiosisGlutathioneeye diseasesNitric oxide synthaseAnalgesics OpioidNG-Nitroarginine Methyl EsterchemistryOpioidAnesthesiaMorphinebiology.proteinsense organsRabbitsmedicine.symptomNitric Oxide SynthaseOpioid receptorMiosiNarcotic Antagonistmedicine.drugEuropean journal of pharmacology
researchProduct

Controlled delivery of naltrexone by an intraoral device: in vivo study on human subjects.

2013

Naltrexone is widely used in the treatment of opiate addiction but its current peroral administration is characterized by low bioavailability with various side effects. The development of a long-acting transbuccal delivery device (IntelliDrug) for NLX may be useful to improve patient compliance and the therapy effectiveness. The aims of the study are (a) to test basic safety and effectiveness of controlled transbuccal drug delivery on human subjects; (b) to compare NLX bioavailability following transbuccal delivery vs per os conventional delivery; and (c) to test the hypothesis that transbuccal delivery is more efficient than the conventional route. In this randomized cross-over pilot study…

Naltrexone HydrochlorideAdultMaleAdolescentNarcotic AntagonistsPharmaceutical ScienceAddictionBiological AvailabilityPharmacologySmoking cessationNaltrexonelaw.inventionTransbuccal drug deliveryYoung AdultDrug Delivery SystemsRandomized controlled triallawmedicineHumansNaltrexone hydrochlorideNLXCross-Over Studiesbusiness.industryAdministration BuccalTransmucosal deliveryBuccal administrationMiddle AgedCrossover studyNaltrexoneBioavailabilitySettore CHIM/09 - Farmaceutico Tecnologico ApplicativoAnesthesiaDelayed-Action PreparationsDrug deliveryMouth ProtectorsFemalebusinessmedicine.drugInternational journal of pharmaceutics
researchProduct